SAS 's medical professionals are participating in more than thirty clinical studies on COVID-19
Researchers are seeking treatments for the disease by testing drugs and alternative therapies using hyperimmune plasma from recovered patients or stem cells from adipose tissue
Healthcare professionals in the Andalusian healthcare system are conducting a total of 32 clinical studies specifically focused on COVID-19. These studies aim to identify effective treatments for the disease and range from testing drugs originally intended for other conditions to evaluating cell therapy.
Andalusia’s leadership in this area is remarkable, as 43.7% of the studies currently underway are sponsored by Andalusian healthcare professionals; specifically, by the Andalusian Network of Foundations Managing Research in the Andalusian Public Health System (RFGI-SSPA), a network coordinated by the Progress and Health Foundation, an entity under the General Secretariat for Health R&D&I that manages and promotes research in all provinces.
Of the 32 clinical studies currently underway, 15 are clinical trials and 17 are observational studies. They focus on various aspects, such as the efficacy of adipose-derived mesenchymal stem cells in patients with severe COVID-19 pneumonia; the effect of sarilumab in adults hospitalized with the disease; the impact of low-molecular-weight heparins on COVID-19 infection; acquired immunity in patients with lung cancer and COVID-19 infection; and respiratory infections in the pediatric population, among others.
The involvement of healthcare professionals in Andalusia extends beyond national borders; specifically, there are five international clinical trials involving hospitals in Cádiz, Málaga, and Seville. Of particular note is the Solidarity study, sponsored by the World Health Organization (WHO), which aims to provide reliable estimates of the effects of antiviral drugs on in-hospital mortality among patients with moderate or severe COVID-19.
The 32 clinical studies currently underway involve a total of 86 participants from healthcare centers in Andalusia; that is, in each clinical study—whether a clinical trial or an observational study—different professionals from different centers are involved, highlighting the multicenter and collaborative nature of all the research being conducted.
Stopping the Spread of COVID-19:
Due to the pandemic declared by the WHO resulting from the novel coronavirus, the Department of Health and Families of the Regional Government of Andalusia has promoted research in this area through a specific research program, with the goal of finding effective treatments for COVID-19. A better understanding of the virus is essential for finding therapeutic alternatives and curbing its spread.
In addition to this extraordinary program related to COVID-19, Andalusia has a Clinical Research Program, a key tool for advancing research that generates knowledge aimed at solving the population’s health problems and improving their life expectancy and quality of life. The clinical research process involves identifying citizens’ health problems, establishing strategies to address them, and evaluating the effectiveness and efficiency of the strategies designed.
🔗 More information: Priego Digital
